SGX:IFAST

iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.

7 February 2026

Earnings Reports·SGX:D05·SGX:IFAST·SGX:O39·SGX:U11·Stock Market

iFAST share price slides 2.6% after Tembusu-linked stake trim; Feb 12 results in focus

iFAST shares fell 2.6% to S$10.60 on Thursday, with 2.07 million shares traded. Tembusu Capital’s deemed stake dipped to 4.97% after CP Invest sold 76,300 shares for S$792,695.96. The drop followed recent volatility and comes ahead of iFAST’s full-year results, set for release after markets close on Feb. 12.

29 January 2026

SGX:IFAST·Stock Market

iFAST share price steadies near S$11 after ShopeePay Money+ launch sparks a jump

iFAST shares rose 0.1% to S$10.97 in Singapore after ShopeePay Malaysia launched Money+, an in-app investment tool built with iFAST and Eastspring. Trading volume dropped to 1.8 million shares from 3.47 million the previous day. Investors await iFAST’s annual results, due Feb. 12.

28 January 2026

Fintech·SGX:IFAST·Stock Market

iFAST share price jumps to S$10.37 — what to watch after SGX’s record close

iFAST Corp shares rose 3.39% to S$10.37 Friday, with 1.93 million shares traded, marking the stock’s highest close since end-2025. The Straits Times Index gained 1.3%, led by surges in UOB and OCBC. iFAST’s recent S$19.575 million deal for a 30% stake in Financial Alliance awaits regulatory approval. Singapore’s core inflation rose 1.2% year-on-year in December; MAS updates its forecasts Jan. 29.

25 January 2026

SGX:IFAST·Singapore Stocks·Stock Market

Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).